Free Access
Issue
J Extra Corpor Technol
Volume 39, Number 1, March 2007
Page(s) 18 - 23
DOI https://doi.org/10.1051/ject/200739018
Published online 15 March 2007
  1. Jenny NS, Mann KG. Coagulation cascade: An overview. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage. Baltimore: Williams Wilkins; 1998; 3. [Google Scholar]
  2. Jasani B, Baxter-Smith DC, Donaldson LJ, Selvam A, Sokhi GS. Topical thrombin and control of wound haematoma. Lancet. 1977;2:332–3. [CrossRef] [Google Scholar]
  3. Hashemi K, Donaldson LJ, Freeman JW, Sokhi GS, Gyde OH, Smith HV. The use of topical thrombin to reduce wound haematoma in patients receiving low-dose heparin. Curr Med Res Opin. 1981;7:458–62. [CrossRef] [PubMed] [Google Scholar]
  4. Suzuki R, Matsuhashi M, Kuwahara T, Kase T. Topical use of thrombin in prostatic surgery. Hinyokika Kiyo. 1986;32:1461–64. [PubMed] [Google Scholar]
  5. Ofodile FA, Sadana MK. The role of topical thrombin in skin grafting. J Natl Med Assoc. 1991;83:416–8. [Google Scholar]
  6. Rousou JA, Engelman RM, Breyer RH. Fibrin glue: An effective hemostatic agent for nonsuturable intra-operative bleeding. Ann Thorac Surg. 1984;38:409–10. [CrossRef] [Google Scholar]
  7. Amrani DL, Diorio JP, Delmotte Y. Wound healing. Role of commercial fibrin sealants. Ann N Y Acad Sci. 2001;936:566–79. [Google Scholar]
  8. Moore M, Burak WJr, Nelson E, et al. Fibrin sealant reduces the duration and amount of fluid drainage after axillary dissection: A randomized prospective clinical trial. J Am Coll Surg. 2001;192:591–9. [CrossRef] [PubMed] [Google Scholar]
  9. Fennis JP, Stoelinga PJ, Jansen JA. Mandibular reconstruction: A clinical and radiographic animal study on the use of autogenous scaffolds and platelet-rich plasma. Int J Oral Maxillofac Surg. 2002;31:281–6. [CrossRef] [Google Scholar]
  10. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91:4–15. [CrossRef] [PubMed] [Google Scholar]
  11. Kajitani M, Ozdemir A, Aguinaga M, Jazieh AR, Flick JT, Antakli T. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg. 2000;15:378–82. [Google Scholar]
  12. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunological impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001;233:88–96. [CrossRef] [PubMed] [Google Scholar]
  13. Beghi E, Gandolfo C, Ferrarese C, et al. Bovine spongiform encephalopathy and Creutzfeldt-Jacob disease: Fact and uncertainties underlying the causal link between animal and human disease. Neurol Sci. 2004;25:122–9. [CrossRef] [PubMed] [Google Scholar]
  14. Cohn E, Oncley J, Strong L, Hughes WJr, Armstrong HJr. Chemical, clinical, and immunological studies on the products of human plasma fractionation I. The characterization of the protein fractions of human plasma. J Clin Invest. 1944;23:417–32. [CrossRef] [PubMed] [Google Scholar]
  15. Fenton J2nd, Fasco M, Stackrow A. Human thrombins. Production, evaluation, and properties of alpha-thrombin. J Biol Chem. 1977;252:3587–98. [CrossRef] [Google Scholar]
  16. Seegers W. Activation of purified prothrombin. Proc Soc Exp Biol Med. 1949;72:677–80. [CrossRef] [Google Scholar]
  17. Denson K. Coagulant and anticoagulant action of snake venoms. Toxicon. 1969;7:5–11. [CrossRef] [PubMed] [Google Scholar]
  18. Masci P, Whitaker A, DeJersy J. Purification and characterization of a prothrombin activator from venom of the Australian brown snake, Pseudonaja textilis textilis. Biochem Int. 1988;17:825–35. [PubMed] [Google Scholar]
  19. Rosing J, Tans G. Structural and functional properties of snake venom prothrombin activators. Toxicon. 1992;30:1515–27. [CrossRef] [PubMed] [Google Scholar]
  20. Stocker K, Hauer H, Muller C, Triplett DA. Isolation and characterization of Textarin, a prothrombin activator from eastern brown snake (Pseudonaja textilis) venom. Toxicon. 1994;32:1227–36. [CrossRef] [PubMed] [Google Scholar]
  21. Kumar V, Madsen T, Zhu H, Semple E. Stability of human thrombin produced from 11 mL of plasma using the thrombin processing device-TPD™. J Extra Corpor Technol. 2005;37:390–5. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  22. Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol. 1957;17:237–46. [CrossRef] [PubMed] [Google Scholar]
  23. Alving B, Weinstein M, Finlayson J, Menitove J, Fratantoni J. Fibrin sealant: summary of a conference on characteristics and clinical uses. Transfusion. 1995;35:783–90. [CrossRef] [PubMed] [Google Scholar]
  24. Semple E, Madsen T, Semple J. Quality of thrombin produced from the patient’s own plasma using the TPD™, a new thrombin processing device. J Extra Corpor Technol. 2005;37:196–200. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  25. Yoshida H, Hirozane K, Kamiya A. Adhesive strength of autologous fibrin glue. Biol Pharm Bull. 2000;23:313–7. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.